NanoSyrinx is a technology company.
NanoSyrinx is a discovery stage synthetic biology company creating a next-generation platform technology for the targeted intracellular delivery of biological molecules.
NanoSyrinx has raised $21.0M across 2 funding rounds.
NanoSyrinx has raised $21.0M in total across 2 funding rounds.
NanoSyrinx is a UK-based, discovery-stage biotechnology company founded in 2020, specializing in synthetic biology to develop Nanosyringes—a genetically encoded platform for targeted intracellular delivery of therapeutic proteins and peptides directly to the cell cytosol.[1][2][3][4] This addresses a key challenge in drug development by enabling access to "undruggable" intracellular targets that traditional therapies cannot reach, serving pharmaceutical developers and patients with unmet needs in areas like oncology and rare diseases.[3][4][5] The company raised £10m in August 2024 from investors including BGF, M Ventures, Octopus Ventures, Eli Lilly, IQ Capital, and others, with its lead product in discovery phase and a key catalyst planned for Q2 2025.[1][4]
Headquartered in Coventry, England, NanoSyrinx builds on academic research from the University of Warwick’s Medical School, positioning it as an emerging player in next-generation therapeutics with strong early validation through awards and high-profile backing.[1][2]
NanoSyrinx was co-founded in 2020 by Dr. Joe Healey (CEO), Dr. Nick Waterfield, and Dr. Alexia Hapeshi to commercialize their breakthrough research on bacterial injection systems from the Waterfield Group at the University of Warwick’s Medical School.[1][2][4] The idea emerged from discovering natural "nanosyringes"—bacterial nanomachines that inject proteins into host cells—which the team engineered into a synthetic biology platform for therapeutic use.[3][4]
Early traction came swiftly: the company secured award recognition and presented at the BIO International Convention in June 2025, highlighting its platform's potential.[1] A pivotal moment was the £10m Series A financing in August 2024, led by prominent VCs and supported by Eli Lilly, fueling advancement toward preclinical milestones.[1][4]
NanoSyrinx rides the synthetic biology and intracellular delivery wave, capitalizing on advances in gene editing and protein engineering to tackle the ~80-90% of human proteome targets inside cells that small molecules and antibodies cannot drug.[3][4][5] Timing is ideal amid surging demand for modalities like ADCs and gene therapies, boosted by post-pandemic biotech funding recovery and AI-driven target discovery.[1]
Market forces favor it: rising investor interest in UK deep tech (e.g., £10m raise despite discovery stage) and regulatory tailwinds for novel platforms position NanoSyrinx to influence the ecosystem by enabling partnerships with big pharma like Eli Lilly for hard-to-treat diseases.[1][4] It exemplifies how academic spinouts are accelerating "cell interior" breakthroughs, potentially reshaping therapeutics for cancer, neurodegeneration, and beyond.[5]
NanoSyrinx is poised for Q2 2025 milestones, likely preclinical data or partnerships, leveraging its fermentation-based scalability to outpace rivals in cost and speed.[1][3] Trends like multimodal therapies and precision payloads will propel it, with influence growing via ecosystem collaborations that democratize intracellular access—echoing its origin as a nimble Warwick spinout now backed by biotech heavyweights.[1][2][4] Investors eye it as a high-upside bet on synthetic biology's next frontier, potentially transforming undruggable targets into viable pipelines.
NanoSyrinx has raised $21.0M in total across 2 funding rounds.
NanoSyrinx's investors include 4BIO Capital, Business Growth Fund, 24Haymarket, Hummingbird Ventures, Octopus Ventures.
NanoSyrinx has raised $21.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $13.0M Series A | 4BIO Capital, Business Growth Fund | |
| Jul 1, 2021 | $8.0M Seed | 24Haymarket, Business Growth Fund, Hummingbird Ventures, Octopus Ventures |